Evidence-Based Type 2 Diabetes Management Algorithm for Indian Government Hospital OPD

DIAGNOSTIC CRITERIA

Diagnose T2DM if any one of the following is present:

Fasting Plasma Glucose (FPG) ≥126 mg/dL (after 8-hour fast)
Random/2-hour post-75g glucose load ≥200 mg/dL
HbA1c ≥6.5% (48 mmol/mol)
Random glucose ≥200 mg/dL with classic symptoms (polyuria, polydipsia, weight loss)

Confirm with repeat testing on a different day unless symptomatic hyperglycemia is present.

BASELINE INVESTIGATIONS (At Diagnosis)

Mandatory tests before initiating therapy:

HbA1c, FPG, PPBG (2-hour post-meal)
Serum creatinine with eGFR calculation
Lipid profile (total cholesterol, LDL, HDL, triglycerides)
Liver function tests (ALT, AST)
Urine albumin-to-creatinine ratio (ACR)
Complete blood count
Vitamin B12 levels (especially if considering metformin)
ECG
Fundoscopy/retinal examination
Foot examination

INDIVIDUALIZED HbA1c TARGETS

Set targets based on patient characteristics 1:

Patient Profile	HbA1c Target
Young (<40 years), newly diagnosed, no complications, no CVD	<6.5%
Most adults with T2DM	<7.0%
History of severe hypoglycemia, limited life expectancy, advanced complications, extensive comorbidities	<8.0%
Elderly (>75 years), frail, high hypoglycemia risk	<8.5%

IMMEDIATE INSULIN INITIATION CRITERIA

Start insulin immediately (regardless of other therapy) if 1:

Blood glucose ≥300 mg/dL (≥16.7 mmol/L), OR
HbA1c >10% (>86 mmol/mol), OR
Symptomatic hyperglycemia (polyuria, polydipsia, weight loss), OR
Evidence of catabolism (unexplained weight loss, ketosis, hypertriglyceridemia)

Insulin regimen for severe hyperglycemia:

Basal insulin (NPH or insulin detemir): Start 0.1-0.2 units/kg/day at bedtime
Titrate by 2-4 units every 3 days based on fasting glucose
Target FPG: 80-130 mg/dL
Once glucose toxicity resolves (typically 2-4 weeks), consider transitioning to oral agents or GLP-1 RA 1

FIRST-LINE THERAPY ALGORITHM

Step 1: Assess for Compelling Indications (Comorbidity-Driven Approach)

This takes priority over glucose-centric approach 1, 2.

If ASCVD present (prior MI, stroke, angina, revascularization):

First choice: GLP-1 RA (liraglutide, dulaglutide, semaglutide) - proven MACE reduction 1
Add: SGLT2i (empagliflozin, canagliflozin, dapagliflozin) for additional CV benefit 1
Add metformin if eGFR ≥30 mL/min/1.73 m² 1

If Heart Failure (HFrEF or HFpEF) present:

First choice: SGLT2i (empagliflozin, dapagliflozin, canagliflozin) - Class I, Level A recommendation 1, 3
Add metformin if eGFR ≥30 mL/min/1.73 m² 1
Avoid: Pioglitazone (contraindicated in HF) 3
Caution: Saxagliptin must be avoided 3

If CKD present (eGFR <60 mL/min/1.73 m² or ACR ≥30 mg/g):

First choice: SGLT2i (empagliflozin, canagliflozin, dapagliflozin) - proven kidney protection 1
Continue SGLT2i until dialysis/transplant for kidney benefit even if glucose-lowering effect minimal at eGFR <45 1
Add: GLP-1 RA for additional kidney benefit 1
Metformin: Use if eGFR ≥30; contraindicated if eGFR <30 1, 4

If Obesity (BMI ≥25 kg/m² for Indians) or weight loss needed:

First choice: GLP-1 RA (semaglutide, dulaglutide, liraglutide) - high to very high weight loss efficacy 1
Alternative: SGLT2i - intermediate weight loss 1
Add metformin - weight neutral to modest loss 1

Step 2: If NO Compelling Indications (Glucose-Centric Approach)

For patients without ASCVD, HF, CKD, or obesity requiring weight loss 1:

Metformin as Foundation 1:

Starting dose: 500 mg once daily with largest meal
Titration: Increase by 500 mg weekly as tolerated
Target dose: 2000 mg/day (1000 mg twice daily with meals)
Maximum dose: 2500 mg/day 4
Extended-release option: Can use once-daily dosing to improve GI tolerability 4

Metformin contraindications:

eGFR <30 mL/min/1.73 m² 1, 4
Acute kidney injury risk
Severe liver disease
Alcohol abuse
Conditions predisposing to lactic acidosis

Metformin adverse effects:

GI intolerance (bloating, diarrhea, abdominal discomfort): Mitigate with slow titration, extended-release formulation, take with food 1
Vitamin B12 deficiency: Monitor periodically and supplement 1
Lactic acidosis: Rare, primarily when eGFR <30 1

ESCALATION ALGORITHM: WHEN TO ADD SECOND AGENT

Add second agent if HbA1c remains ≥1.5% above individualized target after 3 months of metformin at maximum tolerated dose 1.

Dual Therapy Selection (Metformin + Second Agent)

Decision tree based on HbA1c gap and patient factors:

If HbA1c 1.5-2% above target:

Choose based on priority:

If cost is major barrier (Indian government hospital context):
- Sulfonylurea (glimepiride, gliclazide): Most cost-effective
- Starting dose: Glimepiride 1 mg or gliclazide 40 mg once daily before breakfast
- Titration: Increase by 1-2 mg every 1-2 weeks
- Maximum: Glimepiride 4 mg/day, gliclazide 320 mg/day
- High efficacy for glucose lowering 1
- Major risks: Hypoglycemia, weight gain 1
- Avoid in: Elderly, irregular meals, renal impairment (eGFR <30)
If hypoglycemia risk is concern:
- DPP-4 inhibitor (sitagliptin, vildagliptin, teneligliptin): No hypoglycemia risk, weight neutral 1
- Sitagliptin: 100 mg once daily (50 mg if eGFR 30-50,25 mg if eGFR <30)
- Vildagliptin: 50 mg twice daily
- Intermediate efficacy 1
- Do NOT combine with GLP-1 RA 1
If SGLT2i/GLP-1 RA available and affordable:
- Prioritize based on comorbidities as above
- SGLT2i: Intermediate-high efficacy, weight loss, no hypoglycemia 1
- GLP-1 RA: High-very high efficacy, weight loss, no hypoglycemia 1

If HbA1c >2% above target:

Consider initial combination therapy for rapid glycemic control 1
Metformin + SGLT2i + GLP-1 RA if affordable and no contraindications
OR Metformin + Sulfonylurea if cost-limited
OR consider insulin if HbA1c >10% 1

TRIPLE THERAPY ESCALATION

Add third agent if HbA1c remains ≥1.5% above target after 3 months of dual therapy 1.

Triple Therapy Combinations:

Preferred combinations (based on complementary mechanisms):

Metformin + SGLT2i + GLP-1 RA - Most comprehensive benefit 5, 6
Metformin + SGLT2i + DPP-4i - If GLP-1 RA not available/affordable 7
Metformin + Sulfonylurea + SGLT2i - Cost-effective with CV/renal benefit
Metformin + Sulfonylurea + DPP-4i - Most cost-effective, but reduce sulfonylurea dose to minimize hypoglycemia 1

When adding third agent, reassess and reduce sulfonylurea dose by 50% to prevent hypoglycemia 1.

INSULIN INITIATION (Non-Emergency)

Initiate insulin if 1:

HbA1c remains >1.5% above target on triple oral therapy
Progressive β-cell failure
Contraindications to oral agents
Pregnancy planned/occurring

Basal Insulin Regimen (Most Common in Indian OPD)

Starting regimen:

NPH insulin (most cost-effective) or insulin detemir 8
Starting dose: 0.1-0.2 units/kg/day OR 10 units at bedtime
Continue oral agents (except sulfonylurea - reduce by 50% or stop) 1, 6

Titration protocol:

Check fasting glucose daily
Increase by 2 units every 3 days if FPG >130 mg/dL
Decrease by 2-4 units if FPG <70 mg/dL or hypoglycemia occurs
Target FPG: 80-130 mg/dL 8

If post-prandial glucose remains elevated despite basal insulin:

Add rapid-acting insulin (regular insulin or insulin aspart) before largest meal
Starting dose: 4 units or 10% of basal dose
Titrate by 1-2 units every 3 days based on 2-hour post-meal glucose
Target PPBG: <180 mg/dL

Basal-Bolus Insulin (For Advanced Disease)

When to use:

HbA1c >9% despite basal insulin + oral agents
Significant post-prandial hyperglycemia

Regimen:

Basal: NPH at bedtime (50% of total daily dose)
Bolus: Regular insulin before each meal (50% of total daily dose divided among meals)
Total starting dose: 0.4-0.5 units/kg/day 8

RENAL DOSE ADJUSTMENTS

Drug Class	eGFR 45-60	eGFR 30-45	eGFR <30
Metformin	Full dose	Full dose with caution, monitor closely	Contraindicated [1,4]
SGLT2i	Full dose (minimal glucose effect but continue for CV/renal benefit) [1]	Continue for benefit	Continue until dialysis [1]
Sitagliptin	100 mg daily	50 mg daily	25 mg daily
Vildagliptin	50 mg twice daily	50 mg once daily	50 mg once daily
GLP-1 RA	Full dose	Full dose	Use with caution; liraglutide/semaglutide preferred
Sulfonylureas	Reduce dose	Reduce dose or avoid	Avoid (high hypoglycemia risk)
Insulin	Full dose	Full dose	Reduce dose 25% (decreased clearance)

SGLT2 INHIBITOR SPECIFIC GUIDANCE

Dosing 1:

Empagliflozin: 10 mg once daily, increase to 25 mg if needed
Dapagliflozin: 10 mg once daily
Canagliflozin: 100 mg once daily, increase to 300 mg if eGFR ≥60

Critical adverse effects and management 1:

Diabetic ketoacidosis (DKA):
- Rare in T2DM but serious
- Risk factors: Insulin deficiency, acute illness, surgery, prolonged fasting, low-carb diet
- Sick-day protocol: STOP SGLT2i during illness, fasting, or 3-4 days before surgery
- Presentation: May be euglycemic DKA (glucose <250 mg/dL)
- If suspected: Check ketones, stop SGLT2i, give IV fluids and insulin
Genital mycotic infections:
- Common, especially in women
- Prevention: Maintain genital hygiene
- Treatment: Topical antifungals
- Avoid in: Recurrent genital infections
Fournier gangrene (necrotizing fasciitis):
- Extremely rare but life-threatening
- Symptoms: Severe perineal pain, fever, tenderness
- Action: Stop SGLT2i immediately, urgent surgical referral
Volume depletion:
- Monitor blood pressure, especially in elderly or on diuretics
- Ensure adequate hydration
- Adjust diuretics if needed
- Monitor renal function at initiation

GLP-1 RECEPTOR AGONIST SPECIFIC GUIDANCE

Available agents and dosing 1:

Liraglutide (daily injection): Start 0.6 mg daily, increase to 1.2 mg after 1 week, then 1.8 mg if needed
Dulaglutide (weekly injection): Start 0.75 mg weekly, increase to 1.5 mg, then 3 mg, then 4.5 mg
Semaglutide (weekly injection): Start 0.25 mg weekly for 4 weeks, then 0.5 mg, increase to 1 mg, then 2 mg if needed
Oral semaglutide: Start 3 mg daily for 30 days, then 7 mg, increase to 14 mg

Adverse effects 1:

GI effects (nausea, vomiting, diarrhea): Most common
- Mitigate with slow dose titration
- Take with food
- Usually improve after 4-8 weeks
Pancreatitis: Rare; stop if suspected (severe abdominal pain)
Gallbladder disease: Increased risk with rapid weight loss
Contraindications: Personal/family history of medullary thyroid cancer, MEN2 syndrome

HYPOGLYCEMIA MANAGEMENT

Definition:

Level 1: Glucose <70 mg/dL - take action
Level 2: Glucose <54 mg/dL - serious, clinically significant
Level 3: Severe cognitive impairment requiring assistance

Immediate Treatment:

If conscious and able to swallow:

Give 15-20 grams fast-acting carbohydrate:
- 3-4 glucose tablets (5g each), OR
- 150 mL fruit juice, OR
- 3 teaspoons sugar in water
Recheck glucose in 15 minutes
Repeat if still <70 mg/dL
Once glucose >70 mg/dL, give complex carbohydrate meal

If unconscious or unable to swallow:

DO NOT give oral fluids (aspiration risk)
Give 25% dextrose 50-100 mL IV OR glucagon 1 mg IM/SC
Monitor glucose every 15 minutes
Once conscious, give oral carbohydrates

Prevention:

Reduce sulfonylurea/insulin dose when adding SGLT2i or GLP-1 RA 1
Patient education on symptoms and treatment
Regular meal timing
Avoid alcohol on empty stomach

MONITORING AND FOLLOW-UP INTERVALS

Initial Phase (First 3 months):

Visit schedule:

Week 2: Check for adverse effects, medication adherence
Week 4-6: Check FPG, adjust doses
Month 3: HbA1c, FPG, PPBG, renal function, lipids

Stable Phase (After target achieved):

Every 3 months:

HbA1c
FPG and PPBG
Weight, BP
Medication review
Hypoglycemia assessment

Every 6 months:

Renal function (creatinine, eGFR, urine ACR)
Lipid profile
Liver function tests
Vitamin B12 (if on metformin)

Annually:

Comprehensive foot examination
Retinal examination
ECG
Neuropathy assessment

REFERRAL CRITERIA TO ENDOCRINOLOGIST/HIGHER CENTER

Immediate referral:

Suspected DKA or hyperosmolar hyperglycemic state
Severe hypoglycemia with altered consciousness
HbA1c >12% despite triple therapy
Rapid unexplained weight loss with hyperglycemia
Suspected pancreatic disease

Routine referral:

Pregnancy or planning pregnancy
Recurrent severe hypoglycemia
Difficult-to-control diabetes (HbA1c >9% on triple therapy)
Advanced CKD (eGFR <30) requiring insulin adjustment
Proliferative retinopathy
Active diabetic foot ulcer
Need for insulin pump or advanced insulin regimen

SAMPLE INDIAN GOVERNMENT HOSPITAL OPD PRESCRIPTION FORMAT

Patient Name: _________________ Age/Sex: _____ MRD No: _______
Date: __________

Diagnosis: Type 2 Diabetes Mellitus

Baseline Investigations Done:

HbA1c: ____% | FPG: ____ mg/dL | PPBG: ____ mg/dL
eGFR: ____ mL/min/1.73m² | Urine ACR: ____ mg/g
BP: / mmHg | Weight: ____ kg | BMI: ____ kg/m²

Comorbidities: □ ASCVD □ Heart Failure □ CKD □ Obesity □ None

Current HbA1c Target: <____%

PRESCRIPTION:

Example 1: Newly diagnosed, HbA1c 8.5%, no comorbidities, eGFR >60

Tab. Metformin 500 mg - 1 tablet twice daily after meals
(Titrate to 1000 mg twice daily over 4 weeks)
Lifestyle modifications:
- Medical nutrition therapy: 1500-1800 kcal/day, low glycemic index diet
- Physical activity: 150 min/week moderate exercise (brisk walking)
- Weight reduction target: 5-10% if overweight

Follow-up: 2 weeks (adverse effects check), then 3 months (HbA1c)

Example 2: HbA1c 9.2% on metformin 2000 mg/day, has ASCVD, eGFR 55

Tab. Metformin 1000 mg - 1 tablet twice daily after meals (continue)
Inj. Dulaglutide 0.75 mg - subcutaneous once weekly (GLP-1 RA for ASCVD benefit)
Tab. Empagliflozin 10 mg - 1 tablet once daily in morning (SGLT2i for ASCVD + CKD benefit)
Tab. Atorvastatin 40 mg - 1 tablet at bedtime (for ASCVD)

Counseling: SGLT2i sick-day rules, GLP-1 RA injection technique, genital hygiene

Follow-up: 2 weeks (tolerability), 6 weeks (dose adjustment), 3 months (HbA1c, eGFR)

Example 3: HbA1c 10.5%, symptomatic (polyuria, polydipsia), weight loss 5 kg

IMMEDIATE INSULIN INITIATION:

Inj. NPH Insulin - 10 units subcutaneous at bedtime
(Titrate by 2 units every 3 days based on FPG; target FPG 80-130 mg/dL)
Tab. Metformin 500 mg - 1 tablet twice daily after meals
(Start after glucose stabilizes)

Counseling: Insulin injection technique, hypoglycemia recognition and treatment, glucose monitoring

Follow-up: Weekly until FPG stable, then 2 weeks, then monthly

Plan: Once glucose toxicity resolves (4-6 weeks), consider transitioning to GLP-1 RA or adding SGLT2i and reducing insulin

Example 4: HbA1c 8.8% on metformin + glimepiride, has heart failure, eGFR 42

Tab. Metformin 1000 mg - 1 tablet twice daily after meals (continue)
Tab. Glimepiride 2 mg - REDUCE to 1 mg once daily before breakfast (reduce to prevent hypoglycemia)
Tab. Dapagliflozin 10 mg - 1 tablet once daily in morning (SGLT2i for heart failure - Class I indication)

Counseling: SGLT2i sick-day protocol, hypoglycemia symptoms (due to sulfonylurea), volume status monitoring

Follow-up: 2 weeks (BP, volume status, hypoglycemia check), 6 weeks (dose adjustment), 3 months (HbA1c, eGFR)

Plan: Consider stopping glimepiride once HbA1c improves to reduce hypoglycemia risk

Example 5: HbA1c 9.5% on metformin + sitagliptin + glimepiride, cost-limited patient

Tab. Metformin 1000 mg - 1 tablet twice daily after meals (continue)
Tab. Glimepiride 2 mg - REDUCE to 1 mg once daily before breakfast
Tab. Sitagliptin 100 mg - 1 tablet once daily (continue)
Inj. NPH Insulin - 10 units subcutaneous at bedtime
(Add basal insulin; titrate by 2 units every 3 days based on FPG)

Counseling: Insulin injection technique, hypoglycemia recognition (on sulfonylurea + insulin), reduce glimepiride if hypoglycemia occurs

Follow-up: Weekly for first month (insulin titration), then monthly

DECISION TREE SUMMARY

NEW T2DM DIAGNOSIS
        ↓
Check: Glucose ≥300 mg/dL OR HbA1c >10% OR symptomatic?
        ↓
    YES → START INSULIN immediately
        ↓
    NO → Assess comorbidities
        ↓
┌───────────────────────────────────────────────┐
│ ASCVD? → GLP-1 RA + SGLT2i + Metformin       │
│ Heart Failure? → SGLT2i + Metformin           │
│ CKD? → SGLT2i + Metformin (±GLP-1 RA)        │
│ Obesity? → GLP-1 RA + Metformin (±SGLT2i)    │
│ None? → Metformin monotherapy                 │
└───────────────────────────────────────────────┘
        ↓
After 3 months: HbA1c ≥1.5% above target?
        ↓
    YES → Add second agent based on:
          - Comorbidities (SGLT2i/GLP-1 RA)
          - Cost (Sulfonylurea or DPP-4i)
          - Hypoglycemia risk (DPP-4i, SGLT2i, GLP-1 RA)
        ↓
After 3 months: HbA1c still ≥1.5% above target?
        ↓
    YES → Add third agent OR initiate insulin
          - Reduce sulfonylurea dose by 50% when adding
        ↓
After 3 months: HbA1c still ≥1.5% above target?
        ↓
    YES → Initiate/intensify insulin
          - Basal insulin 0.1-0.2 units/kg at bedtime
          - Continue oral agents (reduce/stop sulfonylurea)
          - Consider referral to endocrinologist

KEY PITFALLS TO AVOID

Clinical inertia: Do not delay escalation if HbA1c remains above target for >3 months 1
Hypoglycemia with combination therapy: Always reduce sulfonylurea dose by 50% when adding SGLT2i, GLP-1 RA, or insulin 1
Metformin in renal impairment: Contraindicated if eGFR <30; monitor closely if eGFR 30-45 1, 4
SGLT2i sick-day management: Must stop during acute illness, surgery, or prolonged fasting to prevent DKA 1
DPP-4i + GLP-1 RA combination: Never combine - no additional benefit 1
Pioglitazone in heart failure: Absolutely contraindicated 3
Saxagliptin in heart failure: Must avoid 3
Ignoring comorbidities: Always prioritize SGLT2i for HF/CKD and GLP-1 RA for ASCVD over glucose-centric approach 1, 2
Vitamin B12 deficiency: Monitor periodically in patients on long-term metformin 1
Insulin dose in CKD: Reduce by 25% when eGFR <30 due to decreased clearance

Have a follow-up question?